India Upholds Prevnar 13 Patent In Big Win For Pfizer
Executive Summary
India has awarded Pfizer a patent for its blockbuster pneumonia vaccine Prevnar13, handing the pharmaceutical giant a big victory in a case which has been closely watched as a key test of the country’s patentability criteria.
You may also be interested in...
Serum Institute Awaiting Gavi Push For $2 Pneumococcal Vaccine
Serum Institute hopes to hear by May from Gavi on whether it will consider the firm's $2 per dose pneumococcal conjugate vaccine for immunization programs across developing countries. Its 10-valent vaccine, versus GSK’s 11-valent and Pfizer’s 13-valent vaccines, is 30% cheaper.
India Flouting Own Patent Law By Giving IP Protection To Undeserving Drugs?
India is known for its strict patent legislation restricting which drugs can be given IP protection, but a new study suggests authorities in the country are actually being too lenient in awarding patents in a rush to grant new applications.
US IP Index Based On 'Flawed' Assumptions, Claim Indian Pharma Firms
Indian drug makers have blasted the US Chamber of Commerce’s Global Innovation Policy Center over its International IP Index, saying its compilation is based on a “flawed” assumption that stronger patents drive greater innovation, and that it ignores individual national concerns.